pantoprazole has been researched along with Metastase in 1 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hansen, AR | 1 |
| Tannock, IF | 1 |
| Templeton, A | 1 |
| Chen, E | 1 |
| Evans, A | 1 |
| Knox, J | 1 |
| Prawira, A | 1 |
| Sridhar, SS | 1 |
| Tan, S | 1 |
| Vera-Badillo, F | 1 |
| Wang, L | 1 |
| Wouters, BG | 1 |
| Joshua, AM | 1 |
1 trial available for pantoprazole and Metastase
| Article | Year |
|---|---|
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Disease Progress | 2019 |